Advances in human papillomavirus therapeutic vaccine.
- Author:
Bo LIU
1
;
Qing-zheng ZHAO
Author Information
1. Department of Cellular and Molecular Biology, Cancer Institute, CAMS and PUMC, Beijing 100021, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Cancer Vaccines;
therapeutic use;
Cervical Intraepithelial Neoplasia;
therapy;
virology;
Condylomata Acuminata;
therapy;
virology;
Female;
Humans;
Papillomavirus Infections;
prevention & control;
therapy;
Papillomavirus Vaccines;
therapeutic use;
Uterine Cervical Diseases;
therapy;
virology;
Uterine Cervical Neoplasms;
therapy;
virology
- From:
Acta Academiae Medicinae Sinicae
2007;29(5):685-690
- CountryChina
- Language:Chinese
-
Abstract:
Human papillomavirus (HPV) infection is very common but with limited therapies available. Although the prophylactic vaccination will be promoted worldwide soon, it can only show its benefits decades later. For individuals who already have established infections and dysplasias, it has little efficacy. In contrast, the therapeutic vaccines bridge the temporal deficit by fighting against the established HPV infections and HPV-related diseases. HPV oncogenes may be delivered in viral and bacterial vectors, in peptides or protein, in nucleic acid form, or in cell-based vaccines. This review summarizes the clinical trials of HPV therapeutic vaccines under the way and the different preclinical research strategies that are under investigations.
